DRRX DURECT Corporation

0.69
-0.04  -5%
Previous Close 0.73
Open 0.73
Price To Book 4.31
Market Cap 111837411
Shares 162,059,718
Volume 564,716
Short Ratio
Av. Daily Volume 288,297

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 181227890
  2. 8-K - Current report 181191284
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170474
  4. 8-K - Current report 181166519
  5. 8-K - Current report 181158926

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced July 27, 2018.
RBP-7000
Schizophrenia
Phase 2 trial to be initiated 1Q 2019.
DUR-928
Psoriasis
Phase 2 data due 2019.
DUR-928
Primary sclerosing cholangitis (PSC)
CRL issued February 12, 2014.
Posidur
Post-operative pain relief
CRL issued September 26, 2016. NDA refiled but additional CRL issued August 6, 2018. Noted November 12, 2018 that it will meet with the FDA January 31, 2019 to discuss further.
Remoxy
Chronic pain
CRL Feb 12 2014. Phase 3 commenced November 2015 in response to CRL. Noted October 19, 2017 that primary endpoint was not met.
POSIMIR - PERSIST 3
Post-operative pain relief
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Phase 2 trial to be initiated 1H 2019.
DUR-928
Nonalcoholic steatohepatitis (NASH)
Phase 2 data due 2019.
DUR-928
Alcoholic hepatitis (AH)

Latest News

  1. Edited Transcript of DRRX earnings conference call or presentation 7-Nov-18 9:30pm GMT
  2. Analysis: Positioning to Benefit within News Corporation, DURECT, Ecolab, MiX Telematics, Ship Finance International, and BCE — Research Highlights Growth, Revenue, and Consolidated Results
  3. DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients
  4. DRRX: Protocol Amendment Speeds DUR-928 Ph2 AH Trial. PERSERIS FDA Approval Adds New Revenue Stream
  5. Could DURECT Corporation’s (NASDAQ:DRRX) Investor Composition Influence The Stock Price?
  6. Durect: 3Q Earnings Snapshot
  7. DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate Update
  8. DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call
  9. DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings
  10. Report: Exploring Fundamental Drivers Behind Alder BioPharmaceuticals, DURECT, Mettler-Toledo International, Internap, Career Education, and Approach Resources — New Horizons, Emerging Trends, and Upcoming Developments
  11. DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer
  12. DURECT to Present at the Cantor Fitzgerald Global Healthcare Conference
  13. Is DURECT Corporation’s (NASDAQ:DRRX) Balance Sheet Strong Enough To Weather A Storm?
  14. DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in Taiwan
  15. DURECT Announces Receipt of $5 Million Milestone Payment from Indivior
  16. DURECT to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
  17. FDA Decision Sends Pain Therapeutics Reeling
  18. DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII
  19. Edited Transcript of DRRX earnings conference call or presentation 1-Aug-18 8:30pm GMT

SEC Filings

  1. CT ORDER - Confidential treatment order 181227890
  2. 8-K - Current report 181191284
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170474
  4. 8-K - Current report 181166519
  5. 8-K - Current report 181158926
  6. 8-K - Current report 181137713
  7. 424B2 - Prospectus [Rule 424(b)(2)] 181116172
  8. EFFECT - Notice of Effectiveness 181114799
  9. CORRESP [Cover] - Correspondence
  10. 8-K - Current report 181097873